Plant Allergy is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Plant Allergy have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Plant Allergy compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plant Allergy overview
Plant allergies refer to hypersensitivity reactions triggered by exposure to pollen, certain plants, or their parts, causing allergic symptoms in susceptible individuals. Common plant allergens include pollen from grasses, trees, and weeds, as well as plant proteins or oils found in flowers, fruits, or leaves. Symptoms range from mild to severe and can involve allergic rhinitis (hay fever), conjunctivitis, skin rashes (contact dermatitis), or respiratory issues like asthma. Diagnosis relies on medical history, allergy testing, and identifying specific triggers. Management involves avoidance measures, medications such as antihistamines, nasal sprays, or immunotherapy (allergy shots) to alleviate symptoms and improve quality of life for those affected by plant allergies.
For a complete picture of PTSR and LoA scores for drugs in Plant Allergy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
